These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 31530782)

  • 1. [Efforts to Reduce the Risk of Febrile Neutropenia and to Increase the Response Rate to Docetaxel and Ramucirumab Therapy in Patients with Non-Small Cell Lung Cancer].
    Yamamoto A; Iwata T
    Gan To Kagaku Ryoho; 2019 Sep; 46(9):1421-1425. PubMed ID: 31530782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non-small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L).
    Hata A; Katakami N; Shimokawa M; Mitsudomi T; Yamamoto N; Nakagawa K
    Clin Lung Cancer; 2018 Nov; 19(6):e865-e869. PubMed ID: 30206044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study.
    Kasahara N; Sunaga N; Kuwako T; Naruse I; Imai H; Jingu A; Tsukagoshi Y; Masuda T; Kitahara S; Tsurumaki H; Yatomi M; Hara K; Koga Y; Sakurai R; Mori K; Kaira K; Maeno T; Asao T; Hisada T
    Support Care Cancer; 2020 Oct; 28(10):4825-4831. PubMed ID: 31982960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of primary prophylactic pegylated-granulocyte-colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancer.
    Mouri A; Kaira K; Shiono A; Yamaguchi O; Murayama Y; Kobayashi K; Kagamu H
    Thorac Cancer; 2019 Apr; 10(4):1005-1008. PubMed ID: 30859745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051.
    Miura K; Yamaguchi O; Mori K; Nakamura A; Tamiya M; Oba T; Yanagitani N; Mizutani H; Ninomiya T; Kajiwara T; Ito K; Miyanaga A; Arai D; Kodama H; Kobayashi K; Kaira K
    Sci Rep; 2024 Feb; 14(1):3816. PubMed ID: 38360906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer.
    Hamai K; Miyaka S; Tada S; Fujita S; Hirakawa T; Matsumura M; Ueno S; Tanimoto T; Ishikawa N
    Cancer Rep (Hoboken); 2023 Apr; 6(4):e1793. PubMed ID: 36727271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of pegfilgrastim in patients with non-small cell lung cancer receiving ramucirumab plus docetaxel in Japan.
    Kondo Y; Tachi T; Sakakibara T; Kato J; Kato A; Mizuno T; Miyake Y; Teramachi H
    Support Care Cancer; 2022 Aug; 30(8):6775-6783. PubMed ID: 35524869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
    Brito M; Esteves S; André R; Isidoro M; Moreira A
    Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of response of patients with non-small cell lung cancer to docetaxel (plus ramucirumab) therapy in second-line treatment.
    Takahara Y; Abe R; Nagae S; Tanaka T; Ishige Y; Shionoya I; Yamamura K; Nishiki K; Nojiri M; Kato R; Shinomiya S; Oikawa T
    Thorac Cancer; 2023 Dec; 14(36):3549-3555. PubMed ID: 37964501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer.
    Matsui A; Morise M; Tanaka I; Ozone S; Matsuzawa R; Koyama J; Hase T; Hashimoto N; Sato M; Hasegawa Y
    Cancer Invest; 2020 Aug; 38(7):424-430. PubMed ID: 32643445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Measures to Ensure Safety of Docetaxel plus Ramucirumab for Advanced Non-Small-Cell Lung Cancer as the Second- or Later-Line].
    Takase M; Shibata K; Iwasa K; Shimizu M; Fujii Y; Takahashi M
    Gan To Kagaku Ryoho; 2019 Jun; 46(6):1039-1042. PubMed ID: 31273171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients.
    Shiono A; Kaira K; Mouri A; Yamaguchi O; Hashimoto K; Uchida T; Miura Y; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
    Thorac Cancer; 2019 Apr; 10(4):775-781. PubMed ID: 30809973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
    Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M
    Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
    Yoh K; Hosomi Y; Kasahara K; Yamada K; Takahashi T; Yamamoto N; Nishio M; Ohe Y; Koue T; Nakamura T; Enatsu S; Lee P; Ferry D; Tamura T; Nakagawa K
    Lung Cancer; 2016 Sep; 99():186-93. PubMed ID: 27565938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
    Pérol M; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Kowalyszyn RD; Pikiel J; Lewanski CR; Thomas M; Dakhil S; Kim JH; Karaseva N; Yurasov S; Zimmermann A; Lee P; Carter GC; Reck M; Cappuzzo F; Garon EB
    Lung Cancer; 2016 Mar; 93():95-103. PubMed ID: 26898621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.
    Fernandes R; Mazzarello S; Stober C; Vandermeer L; Dudani S; Ibrahim MF; Majeed H; Perdrizet K; Shorr R; Hutton B; Fergusson D; Clemons M
    Breast Cancer Res Treat; 2017 Jan; 161(1):1-10. PubMed ID: 27783280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of Primary Prophylaxis with Pegfilgrastim after Docetaxel for Castration-Resistant Prostate Cancer].
    Koutake Y; Tsurusaki Y; Fujita T; Inoue D; Hanada K; Nakagawa Y
    Gan To Kagaku Ryoho; 2019 Nov; 46(11):1721-1725. PubMed ID: 31748481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
    Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
    Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk Factors for Febrile Neutropenia Induced by Docetaxel Chemotherapy in Patients with Non-small Cell Lung Cancer.
    Uchida M; Yamaguchi Y; Hosomi S; Ikesue H; Mori Y; Maegawa N; Takano A; Sato Y; Hosohata K; Muroi N; Tomii K; Hashida T; Nakamura T
    Biol Pharm Bull; 2020 Aug; 43(8):1235-1240. PubMed ID: 32435013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.